• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Novel clinical indenoisoquinoline topoisomerase I inhibitors: a twist around the camptothecins.

作者信息

Pommier Yves, Cushman Mark, Doroshow James H

机构信息

Yves Pommier: Developmental Therapeutics Branch and Laboratory of Molecular Pharmacology, Center for Cancer Research, Division of Cancer Treatment and Diagnosis, National Cancer Institute, NIH, Bethesda, Maryland, USA.

出版信息

Oncotarget. 2018 Dec 18;9(99):37286-37288. doi: 10.18632/oncotarget.26466.

DOI:10.18632/oncotarget.26466
PMID:30647868
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6324668/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b49c/6324668/1a47e34935d4/oncotarget-09-37286-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b49c/6324668/1a47e34935d4/oncotarget-09-37286-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b49c/6324668/1a47e34935d4/oncotarget-09-37286-g001.jpg

相似文献

1
Novel clinical indenoisoquinoline topoisomerase I inhibitors: a twist around the camptothecins.新型临床异喹啉拓扑异构酶I抑制剂：喜树碱类药物的新突破
Oncotarget. 2018 Dec 18;9(99):37286-37288. doi: 10.18632/oncotarget.26466.
2
Design, synthesis, and biological evaluation of cytotoxic 11-alkenylindenoisoquinoline topoisomerase I inhibitors and indenoisoquinoline-camptothecin hybrids.细胞毒性11-烯基茚并异喹啉拓扑异构酶I抑制剂及茚并异喹啉-喜树碱杂合物的设计、合成与生物学评价
J Med Chem. 2003 Jul 17;46(15):3275-82. doi: 10.1021/jm0300476.
3
Design, synthesis, and biological evaluation of cytotoxic 11-aminoalkenylindenoisoquinoline and 11-diaminoalkenylindenoisoquinoline topoisomerase I inhibitors.细胞毒性11-氨基烯基茚并异喹啉和11-二氨基烯基茚并异喹啉拓扑异构酶I抑制剂的设计、合成及生物学评价
Bioorg Med Chem. 2004 Oct 1;12(19):5147-60. doi: 10.1016/j.bmc.2004.07.027.
4
Synthesis and anticancer activity of simplified indenoisoquinoline topoisomerase I inhibitors lacking substituents on the aromatic rings.芳香环上无取代基的简化茚并异喹啉拓扑异构酶I抑制剂的合成及抗癌活性
J Med Chem. 2004 Nov 4;47(23):5651-61. doi: 10.1021/jm040025z.
5
Design, synthesis, and biological evaluation of indenoisoquinoline topoisomerase I inhibitors featuring polyamine side chains on the lactam nitrogen.在内酰胺氮上带有多胺侧链的茚并异喹啉拓扑异构酶I抑制剂的设计、合成及生物学评价
J Med Chem. 2003 Dec 18;46(26):5712-24. doi: 10.1021/jm030313f.
6
Circumvention of breast cancer resistance protein (BCRP)-mediated resistance to camptothecins in vitro using non-substrate drugs or the BCRP inhibitor GF120918.利用非底物药物或乳腺癌耐药蛋白（BCRP）抑制剂GF120918在体外规避BCRP介导的对喜树碱类药物的耐药性。
Clin Cancer Res. 2001 Apr;7(4):935-41.
7
Optimization of the indenone ring of indenoisoquinoline topoisomerase I inhibitors.茚并异喹啉拓扑异构酶I抑制剂中茚酮环的优化
J Med Chem. 2007 Sep 6;50(18):4388-404. doi: 10.1021/jm070307+. Epub 2007 Aug 4.
8
Differential induction of topoisomerase I-DNA cleavage complexes by the indenoisoquinoline MJ-III-65 (NSC 706744) and camptothecin: base sequence analysis and activity against camptothecin-resistant topoisomerases I.茚并异喹啉MJ-III-65（NSC 706744）和喜树碱对拓扑异构酶I-DNA切割复合物的差异诱导：碱基序列分析及对喜树碱抗性拓扑异构酶I的活性
Cancer Res. 2003 Nov 1;63(21):7428-35.
9
Bisindenoisoquinoline bis-1,3-{(5,6-dihydro-5,11-diketo-11H-indeno[1,2-c]isoquinoline)-6-propylamino}propane bis(trifluoroacetate) (NSC 727357), a DNA intercalator and topoisomerase inhibitor with antitumor activity.双茚并异喹啉双-1,3-{(5,6-二氢-5,11-二酮-11H-茚并[1,2-c]异喹啉)-6-丙基氨基}丙烷双(三氟乙酸盐)(NSC 727357)，一种具有抗肿瘤活性的DNA嵌入剂和拓扑异构酶抑制剂。
Mol Pharmacol. 2006 Sep;70(3):1109-20. doi: 10.1124/mol.106.024372. Epub 2006 Jun 23.
10
Design, synthesis and biological evaluation of 3-substituted indenoisoquinoline derivatives as topoisomerase I inhibitors.作为拓扑异构酶I抑制剂的3-取代茚并异喹啉衍生物的设计、合成及生物学评价
Bioorg Med Chem Lett. 2016 Feb 1;26(3):1068-1072. doi: 10.1016/j.bmcl.2015.12.014. Epub 2015 Dec 7.

引用本文的文献

1
Design, Synthesis, and Investigation of the Pharmacokinetics and Anticancer Activities of Indenoisoquinoline Derivatives That Stabilize the G-Quadruplex in the Promoter and Inhibit Topoisomerase I.设计、合成及吲哚异喹啉衍生物的药代动力学和抗癌活性研究，该衍生物能稳定启动子中的 G-四链体并抑制拓扑异构酶 I。
J Med Chem. 2024 May 9;67(9):7006-7032. doi: 10.1021/acs.jmedchem.3c02303. Epub 2024 Apr 26.
2
Synthesis and Biological Activity of a New Indenoisoquinoline Copper Derivative as a Topoisomerase I Inhibitor.新型苯并异喹啉铜衍生物的合成及其作为拓扑异构酶 I 抑制剂的生物活性。
Int J Mol Sci. 2023 Sep 26;24(19):14590. doi: 10.3390/ijms241914590.
3

本文引用的文献

1
NCI Comparative Oncology Program Testing of Non-Camptothecin Indenoisoquinoline Topoisomerase I Inhibitors in Naturally Occurring Canine Lymphoma.NCI 比较肿瘤学计划在自然发生的犬淋巴瘤中测试非喜树碱类吲哚喹啉拓扑异构酶 I 抑制剂。
Clin Cancer Res. 2018 Dec 1;24(23):5830-5840. doi: 10.1158/1078-0432.CCR-18-1498. Epub 2018 Jul 30.
2
Roles of eukaryotic topoisomerases in transcription, replication and genomic stability.真核生物拓扑异构酶在转录、复制和基因组稳定性中的作用。
Nat Rev Mol Cell Biol. 2016 Nov;17(11):703-721. doi: 10.1038/nrm.2016.111. Epub 2016 Sep 21.
3
Drugging topoisomerases: lessons and challenges.
Next Generation Gold Drugs and Probes: Chemistry and Biomedical Applications.
下一代金药物和探针：化学与生物医学应用。
Chem Rev. 2023 May 24;123(10):6612-6667. doi: 10.1021/acs.chemrev.2c00649. Epub 2023 Apr 18.
4
Targeting radioresistance and replication fork stability in prostate cancer.靶向前列腺癌的放射抵抗和复制叉稳定性。
JCI Insight. 2022 May 9;7(9):e152955. doi: 10.1172/jci.insight.152955.
5
A Novel Copper(II) Indenoisoquinoline Complex Inhibits Topoisomerase I, Induces G2 Phase Arrest, and Autophagy in Three Adenocarcinomas.一种新型铜（II）茚并异喹啉配合物抑制拓扑异构酶I，诱导三种腺癌的G2期阻滞和自噬。
Front Oncol. 2022 Feb 24;12:837373. doi: 10.3389/fonc.2022.837373. eCollection 2022.
6
Self-Assembled Silk Fibroin-Based Aggregates for Delivery of Camptothecin.用于递送喜树碱的自组装丝素蛋白基聚集体
Polymers (Basel). 2021 Nov 3;13(21):3804. doi: 10.3390/polym13213804.
7
Proteins from the DNA Damage Response: Regulation, Dysfunction, and Anticancer Strategies.DNA损伤反应中的蛋白质：调控、功能障碍与抗癌策略
Cancers (Basel). 2021 Jul 29;13(15):3819. doi: 10.3390/cancers13153819.
8
Copper Complexes as Anticancer Agents Targeting Topoisomerases I and II.作为靶向拓扑异构酶I和II的抗癌剂的铜配合物
Cancers (Basel). 2020 Oct 5;12(10):2863. doi: 10.3390/cancers12102863.
9
Nanotechnology for angiogenesis: opportunities and challenges.纳米技术促进血管生成：机遇与挑战。
Chem Soc Rev. 2020 Jul 21;49(14):5008-5057. doi: 10.1039/c8cs01021h. Epub 2020 Jun 15.
10
The Indenoisoquinoline LMP517: A Novel Antitumor Agent Targeting both TOP1 and TOP2.吲噁并喹啉 LMP517：一种新型靶向 TOP1 和 TOP2 的抗肿瘤药物。
Mol Cancer Ther. 2020 Aug;19(8):1589-1597. doi: 10.1158/1535-7163.MCT-19-1064. Epub 2020 May 19.
靶向拓扑异构酶药物：经验与挑战。
ACS Chem Biol. 2013 Jan 18;8(1):82-95. doi: 10.1021/cb300648v. Epub 2013 Jan 4.
4
Putative DNA/RNA helicase Schlafen-11 (SLFN11) sensitizes cancer cells to DNA-damaging agents.假定的 DNA/RNA 解旋酶 Schlafen-11 (SLFN11) 使癌细胞对 DNA 损伤剂敏感。
Proc Natl Acad Sci U S A. 2012 Sep 11;109(37):15030-5. doi: 10.1073/pnas.1205943109. Epub 2012 Aug 27.
5
Interfacial inhibitors: targeting macromolecular complexes.界面抑制剂：靶向大分子复合物。
Nat Rev Drug Discov. 2011 Dec 16;11(1):25-36. doi: 10.1038/nrd3404.
6
A phase I trial of UCN-01 and prednisone in patients with refractory solid tumors and lymphomas.UCN-01 和泼尼松在难治性实体瘤和淋巴瘤患者中的 I 期临床试验。
Cancer Chemother Pharmacol. 2010 Jan;65(2):383-9. doi: 10.1007/s00280-009-1154-y. Epub 2009 Nov 6.
7
The indenoisoquinoline noncamptothecin topoisomerase I inhibitors: update and perspectives.吲哚并异喹啉类非喜树碱拓扑异构酶 I 抑制剂：最新研究进展及展望。
Mol Cancer Ther. 2009 May;8(5):1008-14. doi: 10.1158/1535-7163.MCT-08-0706. Epub 2009 Apr 21.
8
Synthesis and mechanism of action studies of a series of norindenoisoquinoline topoisomerase I poisons reveal an inhibitor with a flipped orientation in the ternary DNA-enzyme-inhibitor complex as determined by X-ray crystallographic analysis.一系列去甲茚并异喹啉拓扑异构酶I抑制剂的合成及其作用机制研究表明，通过X射线晶体学分析确定，在三元DNA-酶-抑制剂复合物中有一种抑制剂具有翻转的取向。
J Med Chem. 2005 Jul 28;48(15):4803-14. doi: 10.1021/jm050076b.
9
Camptothecin and taxol: discovery to clinic--thirteenth Bruce F. Cain Memorial Award Lecture.喜树碱与紫杉醇：从发现到临床——第十三届布鲁斯·F·凯恩纪念奖讲座
Cancer Res. 1995 Feb 15;55(4):753-60.